Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
387.6 ^USD	-3.60%		-2.58%	+26.45%

May. 08	Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing	MT
May. 03	Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing	MT

Medpace Holdings, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 12, 2024 at 04:16 pm EST

Medpace Holdings, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 498.4 million compared to USD 394.1 million a year ago. Net income was USD 78.3 million compared to USD 68.67 million a year ago. Basic earnings per share from continuing operations was USD 2.55 compared to USD 2.2 a year ago. Diluted earnings per share from continuing operations was USD 2.46 compared to USD 2.12 a year ago.

For the full year, the company reported sales was USD 1,885.84 million compared to USD 1,460 million a year ago. Net income was USD 282.81 million compared to USD 245.37 million a year ago. Basic earnings per share from continuing operations was USD 9.2 compared to USD 7.57 a year ago. Diluted earnings per share from continuing operations was USD 8.88 compared to USD 7.28 a year ago.

Latest news about Medpace Holdings, Inc.

Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing	May. 08	MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing	May. 03	MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing	May. 01	MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating	Apr. 24	MT
Transcript : Medpace Holdings, Inc., Q1 2024 Earnings Call, Apr 23, 2024	Apr. 23
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450	Apr. 23	MT
Medpace Q1 Earnings, Revenue Rise; Updates 2024 Guidance	Apr. 22	MT
Medpace Guides For FY 2024 GAAP EPS of $10.79-$11.47 on Revenue of $2.15-$2.2 Billion, vs CIQ Analyst Consensus of $10.57/Share on Revenue of $2.18 Billion	Apr. 22	MT
Earnings Flash (MEDP) MEDPACE HOLDINGS Posts Q1 Revenue $511M, vs. Street Est of $512M	Apr. 22	MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022.	Apr. 22	CI
Medpace Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Medpace Holdings, Inc. Provides Earnings Guidance for the Full Year 2024	Apr. 22	CI
North American Morning Briefing : Stock Futures -2-	Apr. 22	DJ
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target	Mar. 18	MT
Medpace Holdings Insider Sold Shares Worth $82,321,250, According to a Recent SEC Filing	Mar. 08	MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating	Mar. 08	MT
Medpace Holdings Insider Sold Shares Worth $8,996,033, According to a Recent SEC Filing	Mar. 06	MT
Medpace Holdings Insider Sold Shares Worth $40,291,000, According to a Recent SEC Filing	Mar. 06	MT
Medpace Holdings Insider Sold Shares Worth $597,923, According to a Recent SEC Filing	Mar. 01	MT
Medpace Holdings Insider Sold Shares Worth $53,406,441, According to a Recent SEC Filing	Feb. 23	MT
Medpace Holdings Insider Sold Shares Worth $24,992,323, According to a Recent SEC Filing	Feb. 21	MT
North American Morning Briefing : S&P 500 Seen -2-	Feb. 16	DJ
The latest transactions by star fund managers	Feb. 15
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282	Feb. 15	MT
Tranche Update on Medpace Holdings, Inc.'s Equity Buyback Plan announced on October 24, 2022.	Feb. 13	CI

Chart Medpace Holdings, Inc.

Duration

Period

More charts

Company Profile

Medpace Holdings, Inc. is a global provider of clinical research-based drug and medical device development services. The Company is focused on providing scientifically driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. Its drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Its operations are based in North America, Europe, and Asia.

Sector

Biotechnology & Medical Research

Calendar

2024-05-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Medpace Holdings, Inc: A winning stock that went under the radar

June 29, 2022 at 10:45 am EDT

More Strategies

Ratings for Medpace Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

387.6 USD

Average target price

423.2 USD

Spread / Average Target

+9.17%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDPACE HOLDINGS, INC.	+26.45%	12.43B
MODERNA, INC.	+22.56%	46.4B
IQVIA HOLDINGS INC.	-1.51%	41.75B
LONZA GROUP AG	+48.83%	41.37B
CELLTRION, INC.	-3.42%	29.71B
ICON PUBLIC LIMITED COMPANY	+10.13%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.52B
BIO-TECHNE CORPORATION	-0.14%	12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.13B
UNITED THERAPEUTICS CORPORATION	+18.74%	11.81B

Other Biotechnology & Medical Research